GSK shares dive as falling vaccine sales take the shine off earnings
Summary
GSK saw falling vaccine sales take the shine off earnings, The Independent and the Evening Standard reported on Wednesday 28 October, the drugs giant revealing that vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles and RSV jabs. GSK shares dived as weaker sales and mounting costs unnerved investors, The Guardian reported, the British pharma company reporting declining profits amid weaker vaccine sales and a looming patent loss for a blockbuster HIV drug.
Latest: GSK revealed that vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles and RSV jabs, The Independent and the Evening Standard reported, and The Guardian reported that GSK shares dived as weaker sales and mounting costs unnerved investors.
Written automatically by an AI from the articles' headlines and descriptions. It can contain errors: follow the links to read the articles.
How it unfolded
Wednesday 28 October
GSK revealed that vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles and RSV jabs, The Independent and the Evening Standard reported, and The Guardian reported that GSK shares dived as weaker sales and mounting costs unnerved investors.
- 08:44The Guardian GSK shares dive as weaker sales and mounting costs unnerve investors
- 07:55Evening Standard GSK sees falling vaccine sales take shine off earnings
- 07:53The Independent GSK sees falling vaccine sales take shine off earnings